Effects of chromium picolinate on glycemic control and kidney of the obese zucker rat

Nutrition and Metabolism

Volumn 6, Issue , 2009, Pages

  Mozaffari, Mahmood S ^a   Abdelsayed, Rafik ^a   Liu, Jun Yao ^a   Wimborne, Hereward ^a   El Remessy, Azza ^b   El Marakby, Ahmed ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b UNIVERSITY OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 NITROTYROSINE; 8 HYDROXYDEOXYGUANOSINE; ALBUMIN; CHROMIUM PICOLINATE; COLLAGEN; CYCLOOXYGENASE 2; GLUCOSE; INSULIN; MONOCYTE CHEMOTACTIC PROTEIN 1;

ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DNA DAMAGE; DRUG EFFECT; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HISTOPATHOLOGY; INFLAMMATION; INSULIN BLOOD LEVEL; KIDNEY FUNCTION; MALE; NONHUMAN; OBESITY; OXIDATIVE STRESS; RAT; ZUCKER RAT;

RATTUS;

EID: 74349097354     PISSN: None     EISSN: 17437075     Source Type: Journal    
DOI: 10.1186/1743-7075-6-51     Document Type: Article

References (37)

1. Obesity in the new millennium. JM Friedman, Nature 2000 404 632 634 10766249
2. Update on diabetes mellitus. M Korc, Dis Markers 2004 20 161 165 15502249
3. Pathogenic mechanisms of diabetic complications: Diagnostic biomarkers and prognostic indicators. MS Mozaffari R Abdelsayed SW Schaffer, Predictive Diagnostics and Personalized Treatment: Dream or Reality Edited by Golubnitschaja O Nova Publishers 2009 157 182
4. The burden of diabetes and its complications: trends and implications for intervention. N Chaturvedi, Diabetes Res and Clin Pract 2007 76 3 S12 10.1016/j.diabres.2007.01.019 (Pubitemid 46497505)
5. Obesity and inflammation: A new look at an old problem. S Mehta JA Farmer, Curr Atheroscler Rep 2007 9 134 138 10.1007/s11883-007-0009-4 17877922
6. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. P Dandona A Aljada A Chaudhuri P Mohanty R Garg, Circulation 2005 111 1448 1454 10.1161/01.CIR.0000158483.13093. 9D 15781756
7. Nephropathy in Zucker diabetic fat rat is associated with oxidative and nitrosative stress: prevention by chronic therapy with a peroxynitrite scavenger ebselen. PN Chander O Gealekman SV Brodsky S Elitok A Tojo M Crabtree SS Gross MS Goligorsky, J Am Soc Nephrol 2004 15 2391 2403 10.1097/01.ASN.0000135971. 88164.2C 15339988
8. Early events leading to renal injury in obese Zucker (fatty) rats with type II diabetes. TM Coimbra U Janssen HJ Grone T Ostendorf U Kunter H Schmidt G Brabant J Floege, Kidney Int 2000 57 167 182 10.1046/j.1523-1755.2000.00836.x 10620198
9. Renal cyclooxygenase-2 in obese Zucker (fatty) rats. R Komers J Zdychova M Cahova L Kazdova JN Lindsley S Anderson, Kidney Int 2005 67 2151 2158 10.1111/j.1523-1755.2005.00320.x 15882258
10. Chromium in the prevention and control of diabetes. RA Anderson, Diabetes Metab 2000 26 22 27 10705100
11. Chromium picolinate intake and risk of type 2 diabetes: an evidence-based review by the United States food and drug administration. PR Trumbo KC Ellwood, Nutr Rev 2006 64 357 363 10.1111/j.1753-4887.2006.tb00220.x 16958312
12. The potential value and toxicity of chromium picolinate as a nutritional supplement, weight loss agent and muscle development agent. JB Vincent, Sports Med 2003 33 213 230 10.2165/00007256-200333030-00004 12656641
13. Chromium (III) picolinate produces chromosome damage in Chinese hamster ovary cells. DM Stearns JP Wise Sr SR Patierno KE Wetterhahn, FASEB J 1995 9 1643 1648 8529845
14. The nutritional supplement chromium(III) Tris(picolinate) cleaves DNA. JK Speetjens RA Collins JB Vincent SA Woski, Chem Res Toxicol 1999 12 483 487 10.1021/tx9900167 10368310
15. Cytotoxicity and oxidative mechanisms of different forms of chromium. D Bagchi SJ Stohs BW Downs M Bagchi HG Preuss, Toxicology 2002 180 5 22 10.1016/S0300-483X(02)00378-5 12324196
16. Molecular analysis of hprt mutations induced by chromium picolinate in CHO AA8 cells. VH Coryell DM Stearns, Mutat Res 2006 610 114 123 16877033
17. The safety and efficacy of high-dose chromium. DS Lamson SM Plaza, Altern Med Rev 2002 7 218 235 12126463
18. Tissue and subcellular distribution of chromium picolinate with time after entering the bloodstream. DD Hepburn JB Vincent, J Inorg Biochem 2003 94 86 93 10.1016/S0162-0134(02)00623-2 12620677
19. In vivo distribution of chromium from chromium picolinate in rats and implications for the safety of the dietary supplement. DD Hepburn JB Vincent, Chem Res Toxicol 2002 15 93 100 10.1021/tx010091t 11849034
20. Chromium picolinate does not produce chromosome damage. JR Komorowski D Greenberg V Juturu, Toxicol In Vitro 2008 22 819 826 10.1016/j.tiv.2007.12.007 18261879
21. Effect of chromium niacinate and chromium picolinate supplementation on lipid peroxidation, TNF-alpha, IL-6, CRP, glycated hemoglobin, triglycerides, and cholesterol levels in blood of streptozotocin-treated diabetic rats. SK Jain JL Rains JL Croad, Free Radic Biol Med 2007 43 1124 1131 10.1016/j. freeradbiomed.2007.05.019 17854708
22. Effects of chromium picolinate treatment in uninephrectomized rat. MS Mozaffari C Patel C Ballas SW Schaffer, Metabolism 2005 54 1243 1249 10.1016/j.metabol.2005.04.011 16125537
23. Validation of simple indexes to assess insulin sensitivity during pregnancy in Wistar and Sprague-Dawley rats. J Cacho J Sevillano J de Castro E Herrera MP Ramos, Am J Physiol 2008 295 1269 E1276
24. Reversal of hyperglycemic preconditioning by angiotensin II: Role of calcium transport. V Pastukh S Wu C Ricci M Mozaffari S Schaffer, Am J Physiol 2005 288 1965 H1975
25. Insulin withdrawal induces apoptosis via a free radical-mediated mechanism. C Ricci V Pastukh MS Mozaffari SW Schaffer, Can J Physiol Pharmacol 2007 85 455 464 10.1139/Y07-029 17612655
26. Peroxynitrite mediates retinal neurodegeneration by inhibiting nerve growth factor survival signaling in experimental and human diabetes. TK Ali S Matragoon BA Pillai GI Liou AB El-Remessy, Diabetes 2008 57 889 898 10.2337/db07-1669 18285558
27. The biochemistry of chromium. JB Vincent, J Nutr 2000 130 715 718 10736319
28. Mechanisms of chromium action: low-molecular-weight chromium binding substance. JB Vincent, J Am Col Nutr 1999 18 6 12
29. Role of chromium in human health and in diabetes. WT Cefalu FB Hu, Diabetes Care 2004 27 2741 2751 10.2337/diacare.27.11.2741 15505017
30. Chromium picolinate does not improve key features of metabolic syndrome in obese nondiabetic adults. N Iqbal S Cardillo S Volger LT Bloedon RA Anderson R Boston PO Szapary, Metab Syndr Relat Disord 2009 7 143 150 10.1089/met.2008.0048 19422140
31. Chronic toxicity and carcinogenicity studies of chromium picolinate monohydrate administered in feed to F344/N rats and B6C3F1 mice for 2 years. MD Stout A Nyska BJ Collins KL Witt GE Kissling DE Malarkey MJ Hooth, Food Chem Toxicol 2009 47 729 733 10.1016/j.fct.2009.01.006 19166900
32. Chromium picolinate supplementation attenuates body weight gain and increases insulin sensitivity in subjects with type 2 diabetes. J Martin ZQ Wang XH Zhang D Wachtel J Volaufova DE Matthews WT Cefalu, Diabetes Care 2006 29 1826 1832 10.2337/dc06-0254 16873787 (Pubitemid 44156637)
33. Urinary 8-OHdG: a marker of oxidative stress to DNA and a risk factor for cancer, atherosclerosis and diabetics. LL Wu CC Chiou PY Chang JT Wu, Clin Chim Acta 2004 339 1 9 10.1016/j.cccn.2003.09.010 14687888
34. Effects of chromium on DNA replication in vitro. ET Snow, Environ Health Perspect 1994 102 41 44 10.2307/3431761 7843135
35. Chromium picolinate does not produce chromosome damage in CHO cells. R Gudi RS Slesinski JJ Clarke RH San, Mutat Res 2005 587 140 146 16216543
36. Ectopic lipids and organ function. J Szendroedi M Roden, Curr Opin Lipidol 2009 20 50 56 10.1097/MOL.0b013e328321b3a8 19133412
37. Epicardial fat from guinea pig: a model to study the paracrine network of interactions between epicardial fat and myocardium? J Swifka J Weiss K Addicks J Eckel P Rösen, Cardiovasc Drugs Ther 2008 22 107 114 10.1007/s10557-008- 6085-z 18286362